---
schema_version: "secwatch.filing_event.v1"
accession: "0001872789-25-000016"
form_type: "8-K"
ticker: "EMBC"
cik: "0001872789"
company_name: "Embecta Corp."
filed_at: "2025-05-22T23:59:59+00:00"
generated_at: "2026-05-20T18:53:54.591701+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Embecta reaffirms FY2025 guidance, unveils long-range plan with flat revenue growth, $600M FCF target

## Summary
- Reaffirmed FY2025 guidance: revenue $1.073-1.090B, adjusted EPS $2.70-$2.90, adjusted gross margin 62.75%-63.75%.
- Long-range plan (2025-2028): flattish constant currency revenue CAGR, adjusted operating margin ~28%-30%.
- Targets ~$600M cumulative free cash flow over LRP; plans to repay $450M-$500M of debt.
- Strategic priorities: strengthen core insulin injection business, expand product portfolio, increase financial flexibility through cost savings and debt reduction.
- Inaugural Analyst and Investor Day held May 22, 2025, with webcast and presentation materials available online.

## SEC filing metadata
- accession: 0001872789-25-000016
- form_type: 8-K
- ticker: EMBC
- cik: 0001872789
- company_name: Embecta Corp.
- filed_at: 2025-05-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1872789/000187278925000016/0001872789-25-000016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1872789/000187278925000016/embc-20250522.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001872789-25-000016
- JSON: https://secwatch.observer/filing/0001872789-25-000016.json
- Plain text: https://secwatch.observer/filing/0001872789-25-000016.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.